BioSpace News Archive

Oxeia Biopharmaceuticals today announced two new board members and additions to its executive leadership team.

Intergalactic Therapeutics, a focal non-viral gene therapy company, has announced members of its Scientific Advisory Board (SAB).

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) provided an enrollment update on the phase 1/2 GOBLET study in a poster presentation at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI).

Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers, today announced positive performance evaluation study results for its pancreatic cancer test.

Jnana Therapeutics today announced the appointment of John Throup, Ph.D. as Senior Vice President, Head of Development.

Twist Bioscience Corporation today announced that it will issue its financial results for the fiscal 2022 first quarter ended December 31, 2021, before the opening of the market on Friday, February 4, 2022.

ShouTi Inc., a clinical-stage biopharmaceutical company replacing biologics with world-class small molecule medicines using advanced computational and structure-based technology, announced that Daniel Welch has been named Chairman of the company’s board of directors.

Palleon Pharmaceuticals today announced that the U.S. Food and Drug Administration has cleared the company’s investigational new drug (IND) application for its lead candidate E-602.

Aptorum Group Limited is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug Designation to SACT-1, a repurposed small molecule compound for the treatment of patients with Neuroblastoma.

CDISC today announced three new members have joined its Board of Directors: Karen Curran, Brooke Hinkson, and Lisa Lin each began serving a three-year term at the beginning of the year.